| 000 | 01002 a2200313 4500 | ||
|---|---|---|---|
| 005 | 20250517205944.0 | ||
| 264 | 0 | _c20180403 | |
| 008 | 201804s 0 0 eng d | ||
| 022 | _a1538-3598 | ||
| 024 | 7 |
_a10.1001/jama.2018.0195 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGage, Brian F | |
| 245 | 0 | 0 |
_aGenotype vs Clinically Guided Dosing of Warfarin to Prevent Adverse Events-Reply. _h[electronic resource] |
| 260 |
_bJAMA _c03 2018 |
||
| 300 |
_a1279-1280 p. _bdigital |
||
| 500 | _aPublication Type: Letter; Comment | ||
| 650 | 0 | 4 | _aAlgorithms |
| 650 | 0 | 4 | _aAnticoagulants |
| 650 | 0 | 4 |
_aCytochrome P-450 CYP2C9 _xgenetics |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInternational Normalized Ratio |
| 650 | 0 | 4 | _aPharmacogenetics |
| 650 | 0 | 4 | _aWarfarin |
| 700 | 1 | _aBass, Anne R | |
| 700 | 1 | _aEby, Charles S | |
| 773 | 0 |
_tJAMA _gvol. 319 _gno. 12 _gp. 1279-1280 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1001/jama.2018.0195 _zAvailable from publisher's website |
| 999 |
_c28223652 _d28223652 |
||